Alivus Life Sciences
Ticker > Company >

Alivus Life Sciences share price

Alivus Life Sciences Ltd.

NSE: GLS BSE: 543322 SECTOR: Pharmaceuticals & Drugs  172k   863   204

980.10
+18.30 (1.90%)
BSE: Today, 04:01 PM

Price Summary

Today's High

₹ 988.1

Today's Low

₹ 940.65

52 Week High

₹ 1335

52 Week Low

₹ 647.1

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 12009.45 Cr.

Enterprise Value

₹ 11707.85 Cr.

No. of Shares

12.25 Cr.

P/E

28.36

P/B

4.73

Face Value

₹ 2

Div. Yield

2.3 %

Book Value (TTM)

₹  207.17

CASH

₹ 301.59 Cr.

DEBT

₹ 0 Cr.

Promoter Holding

75 %

EPS (TTM)

₹  34.56

Sales Growth

5.64%

ROE

21.15 %

ROCE

28.31%

Profit Growth

0.84 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year5.64%
3 Year6.59%
5 Year20.83%

Profit Growth

1 Year0.84%
3 Year10.23%
5 Year19.21%

ROE%

1 Year21.15%
3 Year24.45%
5 Year52.42%

ROCE %

1 Year28.31%
3 Year33.52%
5 Year76.58%

Debt/Equity

0

Price to Cash Flow

29.04

Interest Cover Ratio

409.3376

CFO/PAT (5 Yr. Avg.)

0.940123250341867

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2024 75.00 0.00
Jun 2024 82.85 9.47
Mar 2024 82.85 9.47
Dec 2023 82.85 9.47
Sep 2023 82.85 9.47
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company has been maintaining healthy ROE of 24.450422599972% over the past 3 years.
  • Company has been maintaining healthy ROCE of 33.5224582933241% over the past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 409.3376.
  • The Company has been maintaining an effective average operating margins of 29.9850648627715% in the last 5 years.
  • The company has an efficient Cash Conversion Cycle of 76.6284 days.
  • Company has a healthy liquidity position with current ratio of 4.3667.
  • The company has a high promoter holding of 75%.

 Limitations

  • The company has shown a poor revenue growth of 6.59384780552783% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
Net Sales 595.36 572.8 536.6 588.62 506.88
Total Expenditure 428.28 400.25 395.15 429.13 372.52
Operating Profit 167.08 172.56 141.45 159.49 134.36
Other Income 5.37 1.69 3.13 5.49 8.53
Interest 0.4 0.39 0.36 0.35 0.34
Depreciation 13.13 13.18 14.53 14.39 15.09
Exceptional Items 0 0 0 0 0
Profit Before Tax 158.93 160.68 129.68 150.24 127.46
Tax 40.19 41.92 31.74 38.76 32.14
Profit After Tax 118.74 118.77 97.94 111.48 95.32
Adjusted EPS (Rs) 9.69 9.69 7.99 9.1 7.78

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 1537.31 1885.17 2123.21 2161.22 2283.21
Total Expenditure 1065.35 1294.09 1507.15 1518.93 1608.97
Operating Profit 471.96 591.07 616.06 642.29 674.25
Other Income 11.99 0.81 14.7 28.96 12.04
Interest 33.52 87.55 27.96 0.55 1.55
Depreciation 29.37 33.39 37.88 42.09 53.45
Exceptional Items 0 0 0 0 0
Profit Before Tax 421.07 470.94 564.93 628.61 631.29
Tax 107.97 119.36 146.2 161.65 160.4
Net Profit 313.1 351.58 418.72 466.96 470.89
Adjusted EPS (Rs.) 29.04 32.61 34.17 38.11 38.43

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 1.96 1.96 24.51 24.51 24.51
Total Reserves 399.73 750.79 2029.81 2113.7 2307.82
Borrowings 0 0 0 0 0
Other N/C liabilities 16.45 22.89 32.7 67.4 756.95
Current liabilities 1307.46 1444.93 746.8 1014.89 438.77
Total Liabilities 1725.6 2220.57 2833.81 3220.49 3528.05
Assets
Net Block 546.25 572.8 589.76 780.63 805.06
Capital WIP 10.73 14.1 91.69 49.35 101.19
Intangible WIP 0 0 5.27 12.26 4.8
Investments 0.08 0.08 0.08 0.08 0.08
Loans & Advances 8.44 11.06 19.63 9.49 700.92
Other N/C Assets 0 0 0 0 0
Current Assets 1160.11 1622.53 2127.39 2368.68 1916
Total Assets 1725.6 2220.57 2833.81 3220.49 3528.05
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 421.07 470.94 564.93 628.61 631.29
Adjustment 56.74 133.31 70.99 44.62 79.27
Changes in Assets & Liabilities -190.26 -107.58 99.84 -213.66 -134.08
Tax Paid -92.54 -108.56 -138.17 -153.57 -162.96
Operating Cash Flow 195.01 388.11 597.59 306.01 413.52
Investing Cash Flow -50.52 -68.73 -122.23 -146.75 -116.48
Financing Cash Flow -136.55 -213.78 -78.8 -387.59 -279.44
Net Cash Flow 7.94 105.6 396.56 -228.33 17.59

Corporate Actions

Investors Details

PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
promoters 82.85 82.85 82.85 82.85 75.00
nirma limited - - 75.00 75.00 75.00
glenmark pharmaceuticals ... 82.84 82.84 7.84 7.84 -
glenn mario saldanha 0.01 0.01 0.01 0.01 -
PARTICULARS Jun 2022% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
investors 17.15 17.15 17.15 17.15 25.00
massachusetts institute o... - 1.43 1.43 1.43 1.43
polar capital funds plc -... 1.32 - - - 2.79
quant mutual fund - quant... - - - - 1.28

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Glenmark Life Scienc - Quaterly Results 24 Oct, 6:27 PM Glenmark Life Scienc - Quaterly Results 24 Oct, 6:27 PM Glenmark Life Sciences informs about board meeting 17 Oct, 5:22 PM Glenmark Life Sciences reports 18% fall in Q1 net profit 26 Jul, 12:10 PM Glenmark Life Scienc - Quaterly Results 25 Jul, 7:18 PM Glenmark Life Scienc - Quaterly Results 25 Jul, 7:18 PM Glenmark Life Scienc - Quaterly Results 25 Jul, 7:18 PM Glenmark Life Sciences informs about disclosure 16 Jul, 11:36 AM Glenmark Life Sciences informs about analyst meet 22 Jun, 11:15 AM Glenmark Life Sciences reports 33% fall in Q4 net profit 25 Apr, 3:39 PM Glenmark Life Scienc - Quaterly Results 25 Apr, 2:50 PM Glenmark Life Scienc - Quaterly Results 25 Apr, 2:50 PM Glenmark Life Scienc - Quaterly Results 25 Apr, 2:50 PM Glenmark Life Science informs about resignation of director 22 Apr, 2:17 PM Glenmark Life Sciences informs about disclosure 22 Mar, 12:52 PM Nirma acquires majority stake in Glenmark Life Sciences 13 Mar, 12:09 PM Glenmark Life Sciences informs about offer letter 9 Feb, 11:52 AM Glenmark Life Scienc - Quaterly Results 23 Jan, 5:20 PM Glenmark Life Scienc - Quaterly Results 23 Jan, 5:20 PM Glenmark Life Sciences inks pact with Japanese innovator pharmaceutical company 19 Jan, 10:40 AM Glenmark Life Sciences informs about media release 19 Jan, 10:16 AM CCI gives green signal for Nirma’s acquisition in Glenmark Life Sciences 20 Dec, 5:23 PM Glenmark Life Scienc - Quaterly Results 20 Oct, 1:11 PM Glenmark Life Scienc - Quaterly Results 20 Oct, 1:11 PM Glenmark Life Sciences informs about disclosure 26 Sep, 12:53 PM Glenmark Life Sciences informs about withdrawal of voluntary issuer rating 23 Sep, 10:20 AM Glenmark Life Scienc - Quaterly Results 21 Jul, 12:55 PM Glenmark Life Scienc - Quaterly Results 21 Jul, 12:55 PM Glenmark Life Scienc - Quaterly Results 21 Jul, 12:55 PM Glenmark Life Scienc - Quaterly Results 27 Apr, 5:40 PM Glenmark Life Scienc - Quaterly Results 27 Apr, 5:40 PM Glenmark Life Scienc - Quaterly Results 27 Apr, 5:40 PM Glenmark Life Scienc - Quaterly Results 27 Jan, 12:55 PM Glenmark Life Scienc - Quaterly Results 27 Jan, 12:55 PM Glenmark Life Scienc - Quaterly Results 27 Jan, 12:55 PM Glenmark Life Sciences informs about newspaper advertisement 3 Dec, 3:36 PM Glenmark Life Sciences informs about earnings call transcript 27 Oct, 12:04 PM Glenmark Life Sciences informs about earnings call 22 Oct, 4:34 PM Glenmark Life Scienc - Quaterly Results 21 Oct, 1:30 PM Glenmark Life Scienc - Quaterly Results 21 Oct, 1:30 PM Glenmark Life Scienc - Quaterly Results 21 Oct, 1:30 PM Glenmark Life Sciences informs about AGM 30 Aug, 3:54 PM Glenmark Life Sciences informs about monitoring agency report 12 Aug, 5:12 PM Glenmark Life Scienc - Quaterly Results 4 Aug, 6:21 PM Glenmark Life Scienc - Quaterly Results 4 Aug, 6:21 PM Glenmark Life Scienc - Quaterly Results 4 Aug, 6:21 PM Glenmark Life Sciences informs about monitoring agency report 13 May, 4:27 PM Glenmark Life Sciences informs about audio recordings of earnings call 22 Apr, 12:16 PM Glenmark Life Sciences informs about outcome of board meeting 21 Apr, 9:51 AM Glenmark Life Scienc - Quaterly Results 20 Apr, 7:35 PM

Alivus Life Sciences Stock Price Analysis and Quick Research Report. Is Alivus Life Sciences an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Alivus Life Sciences and its performance over the period of time. Alivus Life Sciences stock price today is Rs 983.75.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Alivus Life Sciences cash from the operating activity was Rs 413.515 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Alivus Life Sciences has a Debt to Equity ratio of 0 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Alivus Life Sciences , the EPS growth was 0.841 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Alivus Life Sciences has OPM of 29.5305652470596 % which is a good sign for profitability.
     
  • ROE: Alivus Life Sciences have a healthy ROE of 21.1503 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Alivus Life Sciences is Rs 983.75. One can use valuation calculators of ticker to know if Alivus Life Sciences share price is undervalued or overvalued.
Last Updated on:
Brief about Alivus Life Sciences

Glenmark Life Sciences Limited Financials: Check Share Price, Balance Sheet, Annual Report, Quarterly Results, Shareholding, Company Profile and News for Company Analysis

Glenmark Life Sciences Limited is a leading player in the pharmaceutical industry. The company is engaged in the manufacturing of active pharmaceutical ingredients (APIs) and intermediates. With a focus on research and development, innovation, and quality manufacturing processes, Glenmark Life Sciences has established itself as a reliable and trusted partner in the pharmaceutical sector.

Glenmark Life Sciences Limited - Share Price

Through detailed analysis and research, our pre-built screening tools provide real-time updates on Glenmark Life Sciences Limited's share price. Investors can track and monitor the performance of the stock, enabling them to make informed decisions based on the fluctuations in market prices.

Glenmark Life Sciences Limited - Balance Sheet

The balance sheet is a key financial statement that provides a snapshot of a company's financial position. By utilizing our premium features, investors can access the tools necessary to evaluate Glenmark Life Sciences Limited's balance sheet. Our fair value calculation tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis assist investors in determining the intrinsic value of the stock.

Glenmark Life Sciences Limited - Annual Report

Glenmark Life Sciences Limited's annual reports are available for download on Ticker and serve a crucial role in assessing the company's financial performance and future prospects. These reports provide valuable insights into the company's strategies, achievements, and challenges, providing investors with the necessary information to make well-informed investment decisions.

Glenmark Life Sciences Limited - Dividend

Dividends are an essential consideration for long-term stock investors. The company's dividend history and payout ratio are crucial factors to analyze when assessing the potential returns from investing in Glenmark Life Sciences Limited. Our platform provides comprehensive dividend information to help investors evaluate the company's dividend-paying track record.

Glenmark Life Sciences Limited - Quarterly Result

Our website provides up-to-date information on Glenmark Life Sciences Limited's quarterly results. This allows investors to stay informed about the company's financial performance throughout the year. Combined with our premium tools, investors can analyze the quarterly results and make informed decisions regarding their investments.

Glenmark Life Sciences Limited - Stock Price

The stock price of Glenmark Life Sciences Limited is influenced by various factors, including market conditions, industry performance, and company-specific developments. Our platform offers real-time stock price updates, allowing investors to monitor changes in the stock's valuation.

Glenmark Life Sciences Limited - Price Chart

Our website features comprehensive price charts for Glenmark Life Sciences Limited. These charts provide visual representations of the stock's price movements over specific periods, helping investors identify trends and patterns. By studying price charts, investors can make informed decisions based on historical price movements.

Glenmark Life Sciences Limited - News

Stay updated on the latest news and developments surrounding Glenmark Life Sciences Limited. Our platform provides a dedicated news section that covers important announcements, regulatory updates, and market trends impacting the pharmaceutical industry. Access to timely and relevant news helps investors stay informed and make sound investment decisions.

Glenmark Life Sciences Limited - Concall Transcripts

Glenmark Life Sciences Limited's con-call transcripts are available for download on our website. These transcripts provide detailed insights into management discussions, strategies, and outlooks, which can be instrumental in evaluating the company's potential as an investment.

Glenmark Life Sciences Limited - Investor Presentations

Investor presentations offer valuable information about a company's operations, growth opportunities, and financial performance. Glenmark Life Sciences Limited's investor presentations are easily accessible on our website, providing investors with comprehensive insights into the company's performance.

Glenmark Life Sciences Limited - Promoters

The promoters of Glenmark Life Sciences Limited play a critical role in the company's growth and success. With a significant stake in its operations, they have demonstrated a strong commitment to the company's development. By delving into the promoters' background, investors can gain valuable insights into the company's long-term prospects and feel assured of its sustainability.

Glenmark Life Sciences Limited - Shareholders

The shareholder base of Glenmark Life Sciences Limited is an important aspect to consider for investors. Our platform provides comprehensive information on the company's major shareholders, enabling investors to evaluate the company's ownership structure and potential impact on decision-making.

Please note that our website offers pre-built screening tools, premium features for fair value calculation, and downloadable resources such as annual reports, con-call transcripts, investor presentations, credit ratings, and research reports for Glenmark Life Sciences Limited. These tools and resources are designed to assist long-term stock investors in conducting in-depth stock analysis and making informed investment decisions.

Read More
X